Aurinia’s drug to treat autoimmune kidney disease hits its goals in late-stage trial
Aurinia Pharmaceuticals' experimental drug for lupus nephritis, an autoimmune kidney disease, achieved all efficacy goals in a late-stage clinical trial.
Aurinia Pharmaceuticals () said Wednesday evening that an experimental medicine used to treat patients with lupus nephritis, an autoimmune kidney disease, achieved all primary and secondary efficacy goals in a late-stage
